CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion

Marco Boeri, Anna G Purdum, Jessie Sutphin, Brett Hauber, James A Kaye

Research output: Contribution to journalArticlepeer-review

9 Downloads (Pure)

Abstract

Aims: We evaluated physicians' willingness to trade-off benefits, risks and time to infusion for CAR T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. 

Materials & methods: In a discrete-choice experiment survey, 150 US oncologists/hematologists chose between two hypothetical CAR T-cell treatments defined by six attributes. 

Results: Decreasing time to infusion from 113 to 16 days yielded the greatest change in preference weight (1.91). Physicians were willing to accept a >20% increase in risk of severe cytokine release syndrome and 15% increase in risk of severe neurological events in exchange for an increase in the probability of overall survival at 24 months from 40 to 55%. 

Conclusion: Physicians value reducing time to infusion and will accept incremental increases in serious adverse event risks to gain survival improvements.

Original languageEnglish
JournalFuture oncology (London, England)
Early online date28 Sep 2021
DOIs
Publication statusEarly online date - 28 Sep 2021

Fingerprint

Dive into the research topics of 'CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion'. Together they form a unique fingerprint.

Cite this